Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Buy
60
CPHRF Quote, Financials, Valuation and Earnings
Last price:
$12.27
Seasonality move
:
-6.72%
Day range:
$11.49 - $12.22
52-week range:
$6.63 - $12.50
Dividend yield:
0%
P/E ratio:
11.69x
P/S ratio:
6.33x
P/B ratio:
2.47x
Volume:
2.5K
Avg. volume:
5.6K
1-year change:
52.26%
Market cap:
$311.3M
Revenue:
$50.5M
EPS (TTM):
$1.05
Analysts' Opinion
-
Consensus RatingCipher Pharmaceuticals, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 2 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target DownsideAccording to analysts' consensus price target of --, Cipher Pharmaceuticals, Inc. has an estimated downside of -- from its current price of $12.21.
-
Price Target UpsideAccording to analysts, the highest upside price target is -- representing -100% upside increase from its current price of $12.21.
Fair Value
-
According to the consensus of 2 analysts, Cipher Pharmaceuticals, Inc. has -- downside to fair value with a price target of -- per share.
CPHRF vs. S&P 500
-
Over the past 5 trading days, Cipher Pharmaceuticals, Inc. has overperformed the S&P 500 by 14.09% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Cipher Pharmaceuticals, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Cipher Pharmaceuticals, Inc. has grown year-over-year revenues for 10 quarters straight. In the most recent quarter Cipher Pharmaceuticals, Inc. reported revenues of $12.2M.
Earnings Growth
-
Cipher Pharmaceuticals, Inc. has grown year-over-year earnings for 3 quarters straight. In the most recent quarter Cipher Pharmaceuticals, Inc. reported earnings per share of $0.51.
Enterprise value:
309.3M
EV / Invested capital:
2.35x
Price / LTM sales:
6.33x
EV / EBIT:
18.73x
EV / Revenue:
6.13x
PEG ratio (5yr expected):
0.09x
EV / Free cash flow:
10.45x
Price / Operating cash flow:
10.80x
Enterprise value / EBITDA:
13.03x
Gross Profit (TTM):
$33.2M
Return On Assets:
17.47%
Net Income Margin (TTM):
54.17%
Return On Equity:
24.52%
Return On Invested Capital:
20.02%
Operating Margin:
34.39%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-12-31 | 2024-12-31 | 2025-12-31 | 2024-12-31 | 2025-12-31 | |
| Income Statement | ||||||
| Revenue | $21.2M | $33.4M | $50.5M | $11.8M | $12.2M | |
| Gross Profit | $15.9M | $20.1M | $33.2M | $5.2M | $8.1M | |
| Operating Income | $10M | $5.1M | $16.5M | -$520K | $4.2M | |
| EBITDA | $11.3M | $9.2M | $23.7M | $991K | $6M | |
| Diluted EPS | $0.82 | $0.47 | $1.05 | $0.13 | $0.51 | |
| Period Ending | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $29.3M | $38.2M | $48.3M | $38.5M | $28M | |
| Total Assets | $51.7M | $73.8M | $86M | $162.5M | $156.5M | |
| Current Liabilities | $12.3M | $9.4M | $5.3M | $19.9M | $25M | |
| Total Liabilities | $12.8M | $9.7M | $5.5M | $60.2M | $30.3M | |
| Total Equity | $38.9M | $64.1M | $80.5M | $102.3M | $126.2M | |
| Total Debt | $516K | $428K | $353K | $40.6M | $5.5M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-12-31 | 2024-12-31 | 2025-12-31 | 2024-12-31 | 2025-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $16M | $19.2M | $29.8M | $8.5M | $8.5M | |
| Cash From Investing | -$142.7K | -$78.4M | -$71.1K | $1.3M | -$118.9K | |
| Cash From Financing | -$5.2M | $38.5M | -$40.6M | -$750.8K | -$9.2M | |
| Free Cash Flow | $15.9M | $19.1M | $29.6M | $8.5M | $8.4M | |
CPHRF
Sector
Market Cap
$311.3M
$25.8M
Price % of 52-Week High
98.13%
49.08%
Dividend Yield
0%
0%
Shareholder Yield
4.39%
-1.67%
1-Year Price Total Return
55.32%
-19.04%
Beta (5-Year)
0.146
0.490
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$11.04
200-day SMA
Buy
Level
$10.40
Bollinger Bands (100)
Buy
Level
10.13 - 11.07
Chaikin Money Flow
Buy
Level
21.6K
20-day SMA
Buy
Level
$11.02
Relative Strength Index (RSI14)
Buy
Level
69.72
ADX Line
Buy
Level
11.99
Williams %R
Sell
Level
0
50-day SMA
Buy
Level
$10.91
MACD (12, 26)
Buy
Level
1.63
25-day Aroon Oscillator
Buy
Level
88
On Balance Volume
Neutral
Level
4.8K
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (7.1128)
Buy
CA Score
(Annual)
Level (1.1194)
Sell
Beneish M-Score
(Annual)
Level (-2.2012)
Buy
Momentum Score
Level (7)
Buy
Ohlson Score
Level (-2.5834)
Buy
Piotroski F Score
(Annual)
Level (8)
Buy
Quality Ratio Score
Level (5)
Buy
Fundamental Score
Level (9)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Cipher Pharmaceuticals, Inc. engages in a diversified portfolio of commercial and early to late-stage products. It acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products. It offers dermatology products, hospital acute care products, out-licensed products, and specialty medicine. The company was founded on January 9, 2004 and is headquartered in Mississauga, Canada.
Stock Forecast FAQ
In the current month, CPHRF has received 2 Buy ratings 0 Hold ratings, and 0 Sell ratings. The CPHRF average analyst price target in the past 3 months is --.
-
Where Will Cipher Pharmaceuticals, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Cipher Pharmaceuticals, Inc. share price will drop to -- per share over the next 12 months.
-
What Do Analysts Say About Cipher Pharmaceuticals, Inc.?
Analysts are divided on their view about Cipher Pharmaceuticals, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Cipher Pharmaceuticals, Inc. is a Sell and believe this share price will rise from its current level to --.
-
What Is Cipher Pharmaceuticals, Inc.'s Price Target?
The price target for Cipher Pharmaceuticals, Inc. over the next 1-year time period is forecast to be -- according to 2 Wall Street analysts, 2 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is CPHRF A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Cipher Pharmaceuticals, Inc. is a Buy. 2 of 2 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of CPHRF?
You can purchase shares of Cipher Pharmaceuticals, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Cipher Pharmaceuticals, Inc. shares.
-
What Is The Cipher Pharmaceuticals, Inc. Share Price Today?
Cipher Pharmaceuticals, Inc. was last trading at $12.27 per share. This represents the most recent stock quote for Cipher Pharmaceuticals, Inc.. Yesterday, Cipher Pharmaceuticals, Inc. closed at $12.21 per share.
-
How To Buy Cipher Pharmaceuticals, Inc. Stock Online?
In order to purchase Cipher Pharmaceuticals, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get CPHRF Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
CPHRF
Sector
P/E ratio
11.69x
21.64x
PEG ratio
0.09x
-0.01x
P/B ratio
2.47x
1.75x
Price / LTM sales
6.33x
1.47x
Growth Metrics
CPHRF
Sector
Revenue growth
3.35%
3.32%
Earnings growth
290.51%
12.17%
Revenue (5-year growth)
18.48%
6.21%
Earnings forecast
--
-$0.20
Profitability
CPHRF
Sector
Profitability FY 2025
$33.2M
$2.2M
Return on invested capital
20.02%
-33.48%
Return on assets
17.47%
-30.04%
Return on equity
24.52%
-40.2%
Earnings Date
Last Earnings Date
Nov
6
Next Earnings Date
May
7
Estimated Next Earnings Date
Feb
5
Balance Sheet
CPHRF
Sector
Total cash
$7.5M
$24.2M
Short term investments
--
$23M
Total assets
$156.5M
$69.8M
Long term debt
$5.5M
$2.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 37x
Sell
43
Is AAPL Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 34x
Sell
34
Is GOOGL Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 28x
Alerts
Buy
71
NSA alert for Mar 17
National Storage Affiliates Trust [NSA] is down 1.14% over the past day.
Sell
35
CTRN alert for Mar 17
Citi Trends, Inc. [CTRN] is up 19.05% over the past day.
Buy
64
ESLT alert for Mar 17
Elbit Systems Ltd. [ESLT] is up 16.45% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
